Randal F. Dryer, MD

Randal F. Dryer, MD 
Central Texas Spine Institute, LLP
(Austin, Texas)

Dr. Dryer received his Bachelor of Science with honors from the University of Iowa in 1974.  He graduated from the University of Iowa medical school with an M.D. in 1977, and completed his internship in 1978 followed by a residency in orthopedic surgery in 1982, all at the University of Iowa. Dr. Dryer went on to complete a fellowship in Spine and Hand Surgery at New Addenbrooks Hospital in Cambridge, England in 1984.

He served in the United States Air Force at Wilford Hall, Lackland Air Force Base, San Antonio, Texas and progressed from staff orthopedist to Chief of Orthopedic Surgery by the time of his discharge in 1988. He entered private practice in Austin, Texas where he joined Dr. William P. Taylor at The Austin Back Clinic in 1988.  Several years later the group expanded and became the Central Texas Spine Institute.

Dr. Dryer was board certified by the American Board of Orthopaedic Surgery in 1983 and later became a Fellow in the American College of Surgeons.  He is a member of the Travis County Medical Society, the Texas Medical Association and the Texas Orthopedic Association.  Dr. Dryer is also a member of the North American Spine Society, the Cervical Spine Research Society, the Spine Arthroplasty Society, the Society of Lateral Access Surgery (SOLAS) and a past president of the Texas Spine Society. Dr. Dryer participates in numerous FDA-approved clinical trials and limits his practice to the cervical and lumbar spine.

He is the father of a college-age son and daughter and he and his wife, Michelle have two younger daughters.  In his free time, he enjoys playing tennis and spending time with his family.

In November 2010, Dr. Dryer was recognized as an Industry Leader by Becker Orthopedic & Spine Review.  In February 2011, Becker Orthopedic & Spine Review named Dr. Dryer one of the top 100 spine surgeons in the U.S.

He is a Principal Investigator in a Phase 2 clinical study cleared by the United States Food and Drug Administration (FDA) that will enroll 100 patients with chronic low back pain due to lumbar disc degeneration in 15 centers across the United States and Australia, comparing outcomes at six months in 60 patients receiving MPC injections against 40 patients receiving control injections. The study aims to show that a single minimally-invasive injection of its allogeneic or off-the-shelf disc repair MPC product can regenerate damaged discs, thereby reducing pain, improving function, and avoiding surgery.